Mobile

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Mise à jour : Il y a 4 ans
Référence : NCT00538213

Femme et Homme

  • | Pays :
  • Belgium
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 104887 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104887 are eligible for participation in this study.

Critère d'inclusion

  • Influenza

Liens